Key Meetings Likely To Bring WMS And MGT Closer To Settlement [View article]
May 9 case management conference minutes put in court record yesterday, May 20, but not accessible to public, meeting's developments/minutes were not made public, and neither were the settlement $ that each party was required to submit to judge prior to May 9 conference.
Many motions pending before judge and many upcoming hearings to schedule.....rulings and dates should come very soon.
Near-Term Catalyst Provides Attractive Opportunity For MGT Capital Investors [View article]
jd7,
Absurd, really? You sound like I should be writing at the high level of a scientific paper for an academic journal. This is Seeking Alpha for Pete's sake! Lighten up.
You must remember, predicting the timing of a U.S. District Court scheduling event (Markman Hearing Date) is not a precise science, but an art.
Each district and each judge are different. That is precisely why my article uses case studies from three separate states and districts (Texas, Florida, Massachusetts) instead of 3 cases from one rocket docket district like Virginia Eastern or Wisconsin Western.
With that said, while no one can predict with 100% accuracy the date of such a scheduling decision, you can see from the plethora of patent litigation cases where a Markman Hearing date is set that most all fall within a similar window of 6-9 months after the infringement suits are files. (And sometimes less than 6 months as in WDDD's case)
This Markman Hearing announcement date estimate (by May 25) is directly derived from an average of historical case studies and not out of thin air.
This timely forecast should be very informative to investors who are looking for a very near term catalyst that has proven to drive similar stocks in similar court proceedings higher (+353%) in an average of 138 days.
If you want to profit from a highly predictive event, I would spend more time buying MGT under $4.00 while you still can instead of lamenting about giants and fairies. That kind of talk is what I call absurd.
The facts are easily accessible if you're willing to take the time to listen to conference calls, corporate presentations, and do additional research on the FDA clinical trial process.
Regarding the announcement which management promised in the coming weeks, you'll get your answer in GTXI's February 24, Q4 conference call during this exchange during Q&A with Lazard analyst and GTXI CEO Steiner,
"Ryan Martins - Lazard Capital Markets Another one around the DSMB, (inaudible) meeting again before you get the top-line? Will we just get some update on the safety at that point too?
Mitchell Steiner Yes. So the DSMB meets again in April. And so at that point after the DSMB meets, we’ll make a comment as to the outcome of that meeting."
Not only do I expect an April PR because Steiner told us they would make a comment on the safety review, GTXI also issued a PR on October 26, 2013, after the last DSMB safety review, http://bit.ly/ZUxjYF;highlight=
When you have quality management like GTXI, when they say they are going to do something, they usually do. Therefore, when CEO Steiner tells us a comment is coming in April on the DSMB review, I expect it.
Regarding your other question on the trials ending in May, I will point you toward Citi Global's Healthcare Conference on February 25 and the remarks made during GTXI's corporate presentation which clearly tell us the trial will conclude by the end of May,
"In terms of timing, the studies completely enrolled in December of 2012, five months, so the last patient that will come through will put us in May. So in May is when we expect the last patient to come out."
There was a 25K share block today as well at $4.25
With trials set to end at May 30, some are probably just waiting till closer to that date to add knowing results will come in summer. I think we'll have a run-up starting pretty soon in anticipation of that catalyst.
Also, I expect a PR in the coming weeks as promised by management to update us on the safety board review. This is a very close catalyst that is not on many people's radars. That is why I am adding still here in the low $4.00s ($4.25 today) to my position.
And another clue, over 2.3 million shares purchased by insiders in last 14 months in anticipation of enobosarm/Ostarine Phase III results, http://seekingalpha.co...
And remember that Citi put a $19/share price target on GTXI, and $11/share target for Ostarine alone on expectation of positive Phase III trials to be released this summer!
Bullish Catalysts Make GTx Top Biotech Buy For Q1 2013 [View article]
It is just folks selling, who are tired of waiting for Phase III trial results due out in July. I will be adding if we get back under $4.00 because I like to buy at the same prices as insiders. Patience will be rewarded in the case of GTXI, imo.
Titan Presents Compelling Opportunity Ahead Of PDAC Vote [View article]
Congrats to those holding TTNP through the PDAC votes today. The committee voted today to recommend approval for Probuphine. They also voted the Probuphine was effective and safe.
As I wrote in my article on yesterday, "An Alternative Reading of FDA Briefing Materials on Titan's Probuphine," I did not expect such a stinging report from the FDA reviewers and the press that followed. It looks like that negative market reaction proved to be another opportunity to add to your TTNP positions which I did.
Should be interesting to see how the stock opens on Friday morning, but I would expect that the $2.50 I've been looking for is not far off.
An Alternative Reading Of FDA Briefing Materials On Titan's Probuphine [View article]
Today, the FDA "reviewers" cautioning approval of Probuphine and lemming press who followed did not win. The PDAC voted favorably for Titan's Probuphine on all four votes for efficacy, safety, REMS, and application approval.
This product is greatly needed in this targeted population. And the distinguished committee members determined that Probuphine works, is safe, has a safe risk program, and should be approved by the FDA.
Congrats to those who are still holding shares of TTNP!
An Alternative Reading Of FDA Briefing Materials On Titan's Probuphine [View article]
Looking for help because I can't seem to definitely confirm....but I orginally expected a halt all day tomorrow which is typical on adcom review day but I'm hearing this may not be the case. Can anyone confirm?
Titan Presents Compelling Opportunity Ahead Of PDAC Vote [View article]
I am still holding TTNP based on my complete reading of the briefing materials and added today at $1.07. They proved efficacy in robust separation of Probuphine vs. placebo in opioid-negative urine samples, and showed a safety profile on par with sublingual buprenorphine treatments. Seems the reviewers (statistical & clinical) had to add some cautionary language to stimulate a robust discussion on Thursday at PDAC, but TTNP has done exactly what the FDA asked it to do in the trial design, execution, and results. And most importantly going into Thursday's meeting, the PDAC knows that the epidemic of opioid abuse must have more tools (approved treatment options) in this fight. No reason to panic sell today, imo.
Key Meetings Likely To Bring WMS And MGT Closer To Settlement [View article]
Many motions pending before judge and many upcoming hearings to schedule.....rulings and dates should come very soon.
Near-Term Catalyst Provides Attractive Opportunity For MGT Capital Investors [View article]
This story and growth is just beginning here.....$17.49 by October 10, 2013, is what history tells us could happen to MGT.
Key Meetings Likely To Bring WMS And MGT Closer To Settlement [View article]
Key Meetings Likely To Bring WMS And MGT Closer To Settlement [View article]
Near-Term Catalyst Provides Attractive Opportunity For MGT Capital Investors [View article]
Absurd, really? You sound like I should be writing at the high level of a scientific paper for an academic journal. This is Seeking Alpha for Pete's sake! Lighten up.
You must remember, predicting the timing of a U.S. District Court scheduling event (Markman Hearing Date) is not a precise science, but an art.
Each district and each judge are different. That is precisely why my article uses case studies from three separate states and districts (Texas, Florida, Massachusetts) instead of 3 cases from one rocket docket district like Virginia Eastern or Wisconsin Western.
With that said, while no one can predict with 100% accuracy the date of such a scheduling decision, you can see from the plethora of patent litigation cases where a Markman Hearing date is set that most all fall within a similar window of 6-9 months after the infringement suits are files. (And sometimes less than 6 months as in WDDD's case)
This Markman Hearing announcement date estimate (by May 25) is directly derived from an average of historical case studies and not out of thin air.
This timely forecast should be very informative to investors who are looking for a very near term catalyst that has proven to drive similar stocks in similar court proceedings higher (+353%) in an average of 138 days.
If you want to profit from a highly predictive event, I would spend more time buying MGT under $4.00 while you still can instead of lamenting about giants and fairies. That kind of talk is what I call absurd.
GLTY,
Natty
FDA Upgrades Acura Pharmaceuticals To A Public Health Priority [View article]
http://bit.ly/XT9Jdx
Will 2013 Be A Big Year For GTx? [View article]
The facts are easily accessible if you're willing to take the time to listen to conference calls, corporate presentations, and do additional research on the FDA clinical trial process.
Regarding the announcement which management promised in the coming weeks, you'll get your answer in GTXI's February 24, Q4 conference call during this exchange during Q&A with Lazard analyst and GTXI CEO Steiner,
"Ryan Martins - Lazard Capital Markets
Another one around the DSMB, (inaudible) meeting again before you get the top-line? Will we just get some update on the safety at that point too?
Mitchell Steiner
Yes. So the DSMB meets again in April. And so at that point after the DSMB meets, we’ll make a comment as to the outcome of that meeting."
http://seekingalpha.co...
Not only do I expect an April PR because Steiner told us they would make a comment on the safety review, GTXI also issued a PR on October 26, 2013, after the last DSMB safety review, http://bit.ly/ZUxjYF;highlight=
When you have quality management like GTXI, when they say they are going to do something, they usually do. Therefore, when CEO Steiner tells us a comment is coming in April on the DSMB review, I expect it.
Regarding your other question on the trials ending in May, I will point you toward Citi Global's Healthcare Conference on February 25 and the remarks made during GTXI's corporate presentation which clearly tell us the trial will conclude by the end of May,
"In terms of timing, the studies completely enrolled in December of 2012, five months, so the last patient that will come through will put us in May. So in May is when we expect the last patient to come out."
http://seekingalpha.co...
Those are the facts and available for all to see. Try a little DD next time. GL
Natty
Will 2013 Be A Big Year For GTx? [View article]
With trials set to end at May 30, some are probably just waiting till closer to that date to add knowing results will come in summer. I think we'll have a run-up starting pretty soon in anticipation of that catalyst.
Also, I expect a PR in the coming weeks as promised by management to update us on the safety board review. This is a very close catalyst that is not on many people's radars. That is why I am adding still here in the low $4.00s ($4.25 today) to my position.
Will 2013 Be A Big Year For GTx? [View article]
http://seekingalpha.co...
Will 2013 Be A Big Year For GTx? [View article]
http://bit.ly/10WsUhQ
GTXI will be THE big cancer biotech story this summer as Phase III Ostarine results come in.
Bullish Catalysts Make GTx Top Biotech Buy For Q1 2013 [View article]
Titan Presents Compelling Opportunity Ahead Of PDAC Vote [View article]
As I wrote in my article on yesterday, "An Alternative Reading of FDA Briefing Materials on Titan's Probuphine," I did not expect such a stinging report from the FDA reviewers and the press that followed. It looks like that negative market reaction proved to be another opportunity to add to your TTNP positions which I did.
Should be interesting to see how the stock opens on Friday morning, but I would expect that the $2.50 I've been looking for is not far off.
An Alternative Reading Of FDA Briefing Materials On Titan's Probuphine [View article]
This product is greatly needed in this targeted population. And the distinguished committee members determined that Probuphine works, is safe, has a safe risk program, and should be approved by the FDA.
Congrats to those who are still holding shares of TTNP!
An Alternative Reading Of FDA Briefing Materials On Titan's Probuphine [View article]
Titan Presents Compelling Opportunity Ahead Of PDAC Vote [View article]